左卡尼汀对终末期糖尿病肾病持续性非卧床腹膜透析患者肾性贫血的影响

Clinical observation of L-carnitine in improving renal anemia of continuous ambulatory peritoneal dialysis patients who developed from diabetic nephropathy

目的研究静脉注射左夫尼汀(可益能,LCN)对终末期糖尿病肾病腹膜透析患者肾性贫血的改善作用。方法将终末期糖尿病肾病腹膜透析患者50例随机均分为常规治疗组(A组)和LCN治疗组(B组),B组在常规治疗基础上左卡尼汀每周3次静脉注射,疗程3个月。治疗前后测定血红蛋白、红细胞压积,记录血压升高发生率、促红细胞生成素(EPO)用量。结果B组治疗3个月后血红蛋白、红细胞压积上升幅度明显高于A组。结论对予尿毒症患者联合使用LCN可改善对EPO的敏感性,减少EPO的用量,提高EPO的疗效,并且是安全的。

Objective To assess the efficacy of L-carnitine in the treatment of continuous ambulatory peritoneal dialysis patients with anemia. Methods Fifty patients were randomly divided into 2 group：group A, group B. Two groups were all treated by rHu EPO. In addition, 1 g of L-carnitine was infused three times each week in group B. Results Compared with gruup A, haematocrit （Hct） and haemoglobin （Hb） were all significantly increased （P〈0.05 or 〈0.01 ） in group B. Conclusion Treatment of L-carnitine may improve the sensitivity and effect of rHu EPO. The therapy is safe and effective in the treatment of continuous ambulatory peritoneal dialysis patients with anemia.